Skip to main content
. 2021 Nov 8;73:103679. doi: 10.1016/j.ebiom.2021.103679

Figure 1.

Figure 1

Spike-specific IgG antibodies. Serum spike-specific IgG antibody titers were measured 28 days after the second and third dose of BNT162b2 vaccine in 61 KT recipients. (a) Spike-specific IgG seroconversion rate after the second and third dose; *, p=0.046, [Chi-square test]. (b) Level of spike-specific IgG after the second and third dose in patients who have seroconverted after the second dose. Data are shown as median and interquartile range (IQR). ****p <0·0001, [Wilcoxon matched-pairs, two-tailed rank test].